A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention Development and initial validation by Mehran, Roxana et al.
A
o
A
D
R
Z
A
M
N
R
t
d
i
n
f
i
s
R
(
h
o
c
u
t
C
a
Journal of the American College of Cardiology Vol. 44, No. 7, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.06.068Interventional Cardiology
Simple Risk Score for Prediction
f Contrast-Induced Nephropathy
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ew York, New York
OBJECTIVES We sought to develop a simple risk score of contrast-induced nephropathy (CIN) after
percutaneous coronary intervention (PCI).
BACKGROUND Although several risk factors for CIN have been identified, the cumulative risk rendered by
their combination is unknown.
METHODS A total of 8,357 patients were randomly assigned to a development and a validation dataset.
The baseline clinical and procedural characteristics of the 5,571 patients in the development
dataset were considered as candidate univariate predictors of CIN (increase 25% and/or
0.5 mg/dl in serum creatinine at 48 h after PCI vs. baseline). Multivariate logistic regression
was then used to identify independent predictors of CIN with a p value 0.0001. Based on
the odds ratio, eight identified variables (hypotension, intra-aortic balloon pump, congestive
heart failure, chronic kidney disease, diabetes, age75 years, anemia, and volume of contrast)
were assigned a weighted integer; the sum of the integers was a total risk score for each
patient.
RESULTS The overall occurrence of CIN in the development set was 13.1% (range 7.5% to 57.3% for
a low [5] and high [16] risk score, respectively); the rate of CIN increased exponentially
with increasing risk score (Cochran Armitage chi-square, p  0.0001). In the 2,786 patients
of the validation dataset, the model demonstrated good discriminative power (c statistic 
0.67); the increasing risk score was again strongly associated with CIN (range 8.4% to 55.9%
for a low and high risk score, respectively).
CONCLUSIONS The risk of CIN after PCI can be simply assessed using readily available information. This
risk score can be used for both clinical and investigational purposes. (J Am Coll Cardiol
2004;44:1393–9) © 2004 by the American College of Cardiology FoundationT
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sadiologic procedures utilizing intravascular iodinated con-
rast media injections are being widely applied for both
iagnostic and therapeutic purposes. This has resulted in an
ncreasing incidence of procedure-related contrast-induced
ephropathy (CIN) (1–3). Although the risk of renal
unction impairment associated with radiologic procedures
s low in the general population, it may be very high in
elected patient subsets, especially in cardiac procedures.
eported rates from different centers may vary significantly
4–8).
Many individual risk factors for the development of CIN
ave been reported (1–8). Although the combination of two
r more risk factors is rather common in daily practice, the
umulative risk of several variables on renal function is
nknown. This dictates the need for global assessment of
he impact of these variables on the development of CIN.
From the *Cardiovascular Research Foundation and †Columbia University Medical
enter, New York, New York.
Manuscript received February 4, 2004; revised manuscript received June 14, 2004,pccepted June 22, 2004.he aim of the present study was to develop a simple risk
core that could be readily applied by clinicians to evaluate
ndividual patient risk to develop CIN after percutaneous
oronary intervention (PCI).
ETHODS
onsecutive patients with documented serum creatinine
efore the procedure and at 48 h after the procedure who
nderwent PCI over a period of six years were identified
rom our prospective interventional cardiology data base.
atients with pre-existing end-stage renal disease requiring
ialysis and other contrast exposure within one week or less
rom the index procedure, patients treated with PCI for
cute myocardial infarction, and patients in shock were
xcluded from the analysis.
Patients underwent PCI according to current guidelines
fter written, informed consent was obtained. Routine
ydration was performed with 1 ml/kg/h of half-normal
aline for 4 to 12 h before PCI and 18 to 24 h after PCI. All
atients received 325 mg/day aspirin at least 24 h before the
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Contrast Nephropathy Risk Score October 6, 2004:1393–9rocedure and continued indefinitely. Patients were also
reated with an additional antiplatelet agent: either ticlopi-
ine 250 mg twice daily or clopidogrel 75 mg/day for four
eeks.
linical definitions and follow-up. “Contrast-induced ne-
hropathy” was defined as an increase of25% or0.5 mg/dl
n pre-PCI serum creatinine at 48 h after PCI. “Anemia” was
efined using World Health Organization criteria: baseline
ematocrit value 39% for men and 36% for women (9).
Chronic kidney disease” was baseline serum creatinine of
1.5 mg/dl or an estimated glomerular filtration rate (eGFR)
f 60 ml/min/1.73 m2 (Levey modified MDRD formula)
10,11). “Hypotension” was systolic blood pressure 80 mm
g for at least 1 h requiring inotropic support with medica-
ions or intra-aortic balloon pump (IABP) within 24 h
eriprocedurally. Serum creatinine was measured before the
rocedure and at 48 h after the procedure.
A dedicated data coordinating center performed all data
anagement and analyses. Prespecified clinical and labora-
ory demographic information was obtained from hospital
harts that were reviewed by independent research person-
el who were unaware of the objectives of the study;
ccumulated data were then entered prospectively in the
ata base. These methods for data extraction have been
ublished previously (12,13).
isk score development. Eligible patients from the entire
ata base were randomized in a 2:1 manner to create a
evelopment and validation dataset, respectively. The risk
core development dataset was initially used for identifying
nivariate associations between baseline clinical and key
rocedural characteristics and CIN. Multivariate logistic
egression analysis was then performed to identify indepen-
ent predictors of CIN and to estimate odds ratios (ORs).
isk factors that were significant in the univariate analysis
ere available for selection in the final model; a bootstrap
ethod was used to select the best subset of risk factors to
void overfitting the data. A total of 200 bootstrap samples
ere selected from the development dataset. For each
ample, a stepwise selection procedure was used to choose
ndependent predictors of CIN. Variables that were selected
n at least 90% of the bootstrap models were included in the
nal multivariate models.
Two separate regression models were created: the first
ccounted for baseline serum creatinine value (model A) and
he second accounted for eGFR (model B). The eight
ariables in each of the final models with p  0.0001 were
Abbreviations and Acronyms
CIN  contrast-induced nephropathy
eGFR  estimated glomerular filtration rate
IABP  intra-aortic balloon pump
OR  odds ratio
PCI  percutaneous coronary interventionssigned a weighted integer coefficient value. For this curpose, the estimated ORs from the logistic model were
sed, giving an integer of 2 to each 0.5 value of OR; the
nteger of 1 was given for each 100-ml increment in contrast
edia administered during the procedure; and the integer of
, 4, or 6 was assigned for baseline eGFR 40 to 60, 20 to 40,
nd 20 ml/min/1.73 m2, respectively. The final risk score
epresented the sum of integer coefficients.
The risk score was tested in the validation dataset. Model
iscrimination was assessed by the goodness-of-fit Hosmer-
emeshow statistic, and its predictive performance was
ssessed with the c-statistic.
Finally, the prognostic significance of risk score on rates
f in-hospital dialysis and one-year mortality was estimated.
ESULTS
atients. Of the 8,443 patients with serum creatinine
easured at baseline and 48 h after the procedure, 86
atients were excluded due to exclusion criteria. A total of
,571 patients were assigned to the development dataset.
aseline clinical and angiographic characteristics, as well as
he main procedural data of these patients, are listed in
able 1. Overall, the mean age was 63.6 years old, and there
ere 28.8% females. The median baseline serum creatinine
alue was 1.0 mg/dl (interquartile range 0.9 to 1.2). Chronic
idney disease diagnosed by baseline creatinine 1.5 mg/dl
as present in 585 patients (10.5%), whereas 1,473 patients
26.4%) met the National Kidney Foundation cutoff for
oderate impairment of eGFR 60 ml/min/1.73 m2.
An IABP was applied in a total of 7.1% of patients:
lectively (in the setting other than hypotension/congestive
eart failure) in 3.5% and emergently in 3.6% of patients.
aphenous vein graft lesions were treated in 15.8% of
atients and 4% in conjunction with treatment of a native
essel as well.
Univariate variables associated with CIN are shown in Table
. A total of 16 variables were significantly associated with the
evelopment of CIN. The significant correlates included de-
ographics (age75 years and female gender), risk factors for
oronary artery disease (hypertension, hyperlipidemia, and
iabetes), several co-morbidities (peripheral vascular disease,
revious stroke, chronic kidney disease, advanced congestive
eart failure [New York Heart Association functional class
II/IV], and anemia), acute coronary syndrome at presentation,
nd several angiographic and/or procedural characteristics
multivessel disease, hypotension, IABP use, contrast media
ype, and contrast amount 150 ml).
ultivariate analyses. The multivariate model of predic-
ors of CIN was obtained by using data for all 4,898 patients
ith no missing co-variate values and included 646 (88.6%)
f 729 patients who developed CIN. Hypotension, elective
se of IABP, advanced congestive heart failure, impaired
enal function, age 75 years, anemia, diabetes, and in-
reasing contrast media volume were identified as indepen-
ent predictors of CIN. Given the possible impact of repeat
ontrast exposure on the development of CIN, a repeat
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October 6, 2004:1393–9 Contrast Nephropathy Risk Scorerocedure performed within two weeks from the index
rocedure was forced into the multivariate model as a binary
ariable and was not found to predict independently CIN
OR 1.28, 95% confidence interval 0.70 to 2.33).
Importantly, the same predictors of CIN were identified
y multivariate models, whether baseline plasma creatinine
model A) or eGFR (model B) were used for the definition
f chronic kidney disease (Table 3). The power of the
tatistical association between identified risk factors and
IN assessed by OR was also quite close between the two
odels.
evelopment of risk score. Contrast-induced nephropa-
hy occurred in 729 patients, or 13.1% of the development
et. The incidence of CIN by risk score assignment is
epicted in Figure 1, with significant trends across increas-
ng score values for prediction of CIN (Cochran Armitage
hi-square, p  0.0001). Whether the model used serum
able 1. Clinical and Angiographic Data at Baseline and
rocedural Characteristics (Development Dataset)
Variable
Patients
(n  5,571)
ge (yrs) 63.8  11.2
ge 75 yrs 17.1%
frican American 6.2%
ale 71.2%
iabetes mellitus 30.7%
ypertension 62.1%
ypercholesterolemia 69.8%
moking history 57.7%
ongestive heart failure 6.0%
ody surface area (m2) 1.95  0.22
ypotension 8.3%
cute coronary syndrome 35.7%
revious myocardial infarction 53.4%
revious CABG 39.9%
eripheral vascular disease 18.0%
revious angioplasty 49.4%
aseline hematocrit (%) 40.7 4.9
nemia 25.8%
aseline serum creatinine (mg/dl) 1.12 0.52
1.5 89.5%
1.5–2.0 8.2%
2.0 2.3%
aseline eGFR (ml/min 1.73 m2) 72.7  21.1
60 73.6%
40–60 20.5%
20–40 5.3%
20 0.7%
ultivessel disease 26.9%
ultivessel PCI 26.9%
reated saphenous vein graft 15.8%
ntra-aortic balloon pump* 7.1%
ntra-aortic balloon pump† 3.5%
ontrast amount (ml) 260.9 122
ontrast 150 ml 80.4%
In all patients. †In the setting other than hypotension and/or congestive heart failure.
ata are presented as the mean value  SD or percentage of subjects.
CABG  coronary artery bypass grafting surgery; eGFR  estimated glomerular
ltration rate; PCI  percutaneous coronary intervention.reatinine or eGFR to define risk attributed to chronic aidney disease, the c-statistic was very close (0.69 and 0.70,
espectively). The Hosmer-Lemeshow statistic was chi-
quare  8.05 (p  0.43) for the score with creatinine and
hi-square  8.13 (p  0.42) for the score with eGFR,
ndicating that a logistic model was appropriate in both
nalyses.
Based on the obtained frequencies of CIN in relation to
ifferent risk score, 4,898 patients were further categorized into
our groups: relatively low risk (n 2,898 [59.2%]), moderate
isk (n 1,555 [31.7%]), high risk (n 389 [7.9%]), and very
igh risk (n 56 [1.1%]), corresponding to risk scores of5,
to 10, 11 to 15, and 16, respectively.
alidation of risk score. Contrast-induced nephropathy
ccurred in 386 (13.9%) of 2,786 patients of the validation
et. The rates of CIN in the validation set were close to
hose in the development set inside each of the four risk
roups (Fig. 2). The developed CIN model demonstrated
ood discriminative power in the validation population
c-statistic  0.67).
isk score and outcome after PCI. The ability of the risk
core to predict the rates of post-PCI dialysis and one-year
ortality was further evaluated separately in the develop-
ent and validation sets. Significant increases in rates of
ialysis (Fig. 3) and one-year mortality (Fig. 4) were
bserved with increments of risk score (Cochran-Armitage
rend test, p  0.0001) in both sets.
ISCUSSION
evelopment of CIN after percutaneous endovascular pro-
edures has been associated with several baseline patient
haracteristics and procedural variables, and confers unfa-
orable prognosis. The risk of CIN and its detrimental
onsequences have been shown to be present in both
atients with and without chronic kidney disease and to
ncrease in diabetic patients (1–8). However, other reported
isk factors for CIN have not been examined as additive to
he above, and practical, readily applicable methods to assess
he CIN risk in patients undergoing PCI have not been
pecifically developed.
In the present study, we proposed a CIN risk stratifica-
ion score based on 8 readily available variables, and we
howed that an increasing score number confers exponen-
ially increased CIN risk. The variables included in the
IN risk score are: 1) patient-related characteristics (i.e.,
ge 75 years, diabetes mellitus, chronic congestive heart
ailure, or admission with acute pulmonary edema, hypo-
ension, anemia, and chronic kidney disease); and
) procedure-related characteristics (i.e., the use of elective
ABP or increasing volumes of contrast media). The main
esults of this study are also summarized schematically in
igure 5.
This proposed simple risk score for CIN allows for
mmediate identification of the variables accounted for
efore the procedure and appropriate (and timely) risk
llocation. This is particularly important because treatment
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Contrast Nephropathy Risk Score October 6, 2004:1393–9f CIN is rather limited, and the development of this
omplication is associated with a prolonged hospital stay
nd unfavorable in-hospital and one-year outcomes (1–8).
nce CIN is established, only supportive care is currently
rovided until renal function resolves; infrequently, hemo-
ialysis may be required, either transiently or even perma-
ently. Although a recent single-center report indicated that
eri-PCI hemofiltration starting before PCI and extending
or 24 h after the PCI may decrease the incidence of CIN in
igh-risk patients, this approach has not been yet been
idely adopted in clinical practice (14). Therefore, pres-
ntly, the main method to tackle this complication is its
Table 2. Association of Baseline Clinical, Ang
After Percutaneous Coronary Intervention (De
Variable
Patients
(%)
Chronic kidney disease 8.1
Congestive heart failure* 6.0
Hypotension 8.3
Intra-aortic balloon pump use 3.5
Anemia 25.8
Age 75 yrs 17.1
Diabetes mellitus 30.7
Peripheral vascular disease 18.0
Female gender 28.8
Hypertension 62.1
Prior stroke 11.0
Contrast type (Ioxaglate) 49.9
Multivessel disease 26.5
Acute coronary syndrome 35.7
Hypercholesterolemia 69.8
Contrast amount 80.4
*New York Heart Association functional classification III/IV
CI  confidence interval; CIN  contrast-induced neph
able 3. Multivariate Predictors of CIN After Percutaneous Coro
Variable Integer Score
odel A*
Hypotension 5
Intra-aortic balloon pump use 5
Congestive heart failure‡ 5
Serum creatinine 1.5 mg/dl 4
Age 75 yrs 4
Anemia 3
Diabetes mellitus 3
Contrast volume 1 for 100 ml
odel B†
Congestive heart failure‡ 5
Hypotension 5
Intra-aortic balloon pump use 5
Age 75 yrs 4
Anemia 3
Diabetes mellitus 3
Contrast volume 1 for 100 ml
Estimated glomerular filtration rate
(ml/min 1.73 m2)
2 for 40 to 60,
4 for 20 to 40,
6 for 20
Using serum creatinine as a criterion for renal function. †Using estimated glomerula
lassification III/IV and/or history of pulmonary edema.Abbreviations as in Table 2.revention. We believe that adequate risk assessment before
CI offers a greater opportunity to do so, especially because
he factors included in the risk score described are readily
vailable.
The methodologic inclusion of two procedural vari-
bles with baseline characteristics in the CIN risk score
arrants specific mention. Elective IABP insertion may
e linked with CIN through various mechanisms: 1) as a
arker of significant hemodynamic disturbances during
CI; 2) as a marker of very severe atherosclerotic disease
ithout hypotension; 3) as a source of atheroemboli to
he renal circulation during insertion, pulsation, or re-
phic, and Procedural Characteristics and CIN
ment Dataset, Univariate Analysis)
ence of
(%) OR 95% CI p Value
0.0 2.89 2.32–3.59 0.0001
8.5 2.68 2.09–3.44 0.0001
6.4 2.36 1.89–2.95 0.0001
4.9 2.05 1.47–2.87 0.0001
1.4 2.02 1.72–2.36 0.0001
1.8 1.90 1.59–2.27 0.0001
9.2 1.73 1.48–2.02 0.0001
9.6 1.61 1.35–1.93 0.0001
8.3 1.54 1.31–1.80 0.0001
5.9 1.45 1.24–1.71 0.0001
8.0 1.37 1.10–1.71 0.0007
5.9 1.29 1.09–1.52 0.0006
6.7 1.20 1.03–1.40 0.003
5.8 1.20 1.03–1.40 0.02
3.2 0.75 0.64–0.88 0.0004
4.6 1.24 1.01–1.54 0.045
or history of pulmonary edema.
y; OR  odds ratio.
Intervention (Development Dataset)
Model
Coefficient OR 95% CI p Value
0.9310 2.537 1.973–3.262 0.0001
0.8910 2.438 1.677–3.544 0.0001
0.8111 2.250 1.682–3.011 0.0001
0.7194 2.053 1.586–2.658 0.0001
0.6133 1.847 1.509–2.260 0.0001
0.4705 1.601 1.328–1.930 0.0001
0.4109 1.508 1.260–1.806 0.0001
0.2549 1.290 1.210–1.375 0.0001
0.9923 2.698 2.019–3.603 0.0001
0.9845 2.676 2.082–3.441 0.0001
0.9350 2.547 1.751–3.706 0.0001
0.7861 2.195 1.780–2.706 0.0001
0.6028 1.827 1.518–2.199 0.0001
0.4681 1.597 1.335–1.910 0.0001
0.2434 1.276 1.197–1.360 0.0001
0.1772 1.194 1.099–1.297 0.0001
tion rate as a criterion for renal function. ‡New York Heart Association functionaliogra
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October 6, 2004:1393–9 Contrast Nephropathy Risk Scoreoval; 4) as a partial occlusion of the renal blood flow if
t is positioned too low (i.e., in the abdominal instead of
he descending thoracic aorta); and 5) as a marker of
ncreased vascular complications and post-PCI hypoten-
ion. We have shown in another report that both peri-
CI hypotension and use of IABP without hypotension
re powerful predictors of CIN (15); inclusion of elective
ABP use for any reason in the risk score estimation
ssentially addresses both of these factors.
Contrast media volume has been linked to CIN after PCI
n several studies, but without a firm description of the
ature of the association. We previously reported that the
atio of contrast volume over body surface area may be of
articular importance (15). In this analysis, both the volume
nd the ratio could have been used in the CIN risk score
ith essentially interchangeable results. We opted for in-
lusion of the total volume because it is more easily
pplicable and allows for practically easier risk score calcu-
igure 2. The contrast-induced nephropathy risk score derived from the
evelopment dataset predicted this complication in the validation set, as
igure 1. Risk score development dataset. Increasing risk of contrast-indu
aseline serum creatinine value or estimated glomerular filtration rate in t
estimated glomerular filtration rate-based model.ell. Solid bars  development dataset; open bars  validation dataset. bation. Given not only the absence of therapeutic measures
or CIN but also the very small number of preventive
easures that have been proven effective in randomized
rials (4), it is important to understand that avoidance of
ABP and use of lower volume of contrast media, when
ossible, may afford a sufficient reduction in the patient’s
IN risk with a potentially rewarding outcome. This
ntriguing observation should be further explored prospec-
ively.
Finally, use of the CIN risk score described offers a great
nvestigational tool in future studies regarding CIN preven-
ion. It is possible that certain measures may be very effective
n the prevention of CIN only in certain risk score-based
atient subsets. For example, debate already exists on
hether N-acetyl-L-cysteine is effective in high-risk pa-
ients (large contrast volume, complex angioplasty proce-
ures), whereas data are more supportive of its utility in
atients at relatively low risk of CIN (low contrast volume,
igure 3. In-hospital hemodialysis can be predicted by a high or very high
isk score value similarly in the development and validation datasets. Solid
ephropathy with increasing risk score is evident with inclusion of either
ltivariate model. Solid bars  serum creatinine-based model; open barsced n
he muars  development dataset; open bars  validation dataset.
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Contrast Nephropathy Risk Score October 6, 2004:1393–9iagnostic procedures) (4,16–18). On one hand, it would be
etrimental to entirely dismiss a preventive measure because
t may not prevent CIN in high-risk subsets, but it would
lso be inappropriate to apply universally a preventive
easure to all patients receiving contrast media if it is only
ffective in a certain subgroup. Use of the CIN risk score
ay help clarify such controversial issues and potentially
ead to patient subset-oriented recommendations.
tudy limitations. Although the data were collected pro-
pectively by independent monitors and entered into a
edicated database, this was a post hoc analysis. Due to
igure 4. The prognostic significance of the proposed risk score for
ontrast-induced nephropathy extended to prediction of one-year mortal-
ty, as indicated by the results obtained from both the development and
alidation datasets. Solid bars  development dataset; open bars 
alidation dataset.
igure 5. Scheme to define contrast-induced nephropathy (CIN) risk scor
HF  congestive heart failure class III/IV by New York Heart Assoc
lomerular filtration rate; hypotension  systolic blood pressure 80 mm
alloon pump (IABP) within 24 h periprocedurally.imited availability of data fields, we could not consider
eriprocedural hydration volume, proteinuria, urine output,
nd nephrotoxic medications for inclusion in the risk score
arameters. We did not use creatinine clearance value based
n 24-h urine collection during a true baseline clinical
ondition, and our eGFR calculation is subject to limita-
ions due to the formula used and the possibility that
atients may not be at their true baseline condition before
CI because of dehydration or cardiac illness; however, we
elieve that the assessment of CIN risk based on the utilized
utoffs of serum creatinine and eGFR is fairly accurate for
he clinical purposes of this study and certainly more
ractical and readily available than direct measurement of
reatinine clearance. Although the rise in serum creatinine
ccurs within the first 24 h after exposure to contrast media
n 80% of the patients, the absence of data on serum
reatinine later than 48 h after PCI in the present study
ight result in the slight underestimation of CIN (19).
owever, it is doubtful that a delayed creatinine elevation in
atients without a significant rise within 48 h after PCI may
e at all clinically significant (20). Finally, prospective
alidation of the proposed CIN risk score is warranted in
ther data bases that may provide such ability.
onclusions. Individual patient risk for CIN after PCI can
e globally assessed with the calculation of a simple risk
core based on readily available information. This CIN risk
emia  baseline hematocrit value 39% for men and 36% for women;
classification and/or history of pulmonary edema; eGFR  estimated
r at least 1 h requiring inotropic support with medications or intra-aortice. An
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urposes.
eprint requests and correspondence: Dr. George Dangas,
olumbia University Medical Center, Cardiovascular Research
oundation, 55 East 59th Street, 6th Floor, New York, New York
0022. E-mail: gdangas@crf.org.
EFERENCES
1. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after
coronary intervention. Incidence, risk factors, and relationship to
mortality. Am J Med 1997;103:368–75.
2. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications
of further renal function deterioration within 48 hours of interven-
tional coronary procedures in patients with pre-existent chronic kidney
disease. J Am Coll Cardiol 2000;36:1542–8.
3. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunc-
tion after myocardial revascularization: risk factors, adverse outcomes,
and hospital resource utilization. The Multicenter Study of Postoper-
ative Ischemia Group. Ann Intern Med 1998;128:194–203.
4. McCullough PA. Beyond serum creatinine: defining the patient with
renal insufficiency and why? Rev Cardiovasc Med 2003;4 Suppl
1:S2–6.
5. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic
importance of acute renal failure after percutaneous coronary interven-
tion. Circulation 2002;105:2259–64.
6. Gruberg L, Dangas G, Mehran R, et al. Acute renal failure requiring
dialysis after percutaneous coronary interventions. Cathet Cardiovasc
Interv 2001;52:409–16.
7. Gruberg L, Dangas G, Mehran R, et al. Clinical outcome following
percutaneous coronary interventions in patients with chronic renal
failure. Cathet Cardiovasc Interv 2002;55:66–72.
8. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the
incidence and outcome of contrast-induced nephropathy after percu-
taneous coronary intervention. J Invasive Cardiol 2003;15:18–22.9. Nutritional anemias: report of a WHO Scientific Group. Geneva:
World Health Organization, 1968.
0. National Kidney Foundation. K/DOQI: Clinical practice guidelines
for chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 2002;39 Suppl 1:S1–237.
1. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney
function as a risk factor for atherosclerotic cardiovascular outcomes in
the community. J Am Coll Cardiol 2003;41:47–55.
2. Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden
and CK-MB enzyme elevation after coronary interventions: intravascular
ultrasound study of 2,256 patients. Circulation 2000;101:604–10.
3. Dangas G, Mintz GS, Mehran R, et al. Preintervention arterial
remodeling as an independent predictor of target-lesion revasculariza-
tion after nonstent coronary intervention: an analysis of 777 lesions
with intravascular ultrasound imaging. Circulation 1999;99:3149–54.
4. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-
agent-induced nephropathy by hemofiltration. N Engl J Med 2003;
349:1333–40.
5. Dangas G, Iakovou I, Nikolsky E, et al. Acute nephropathy after
percutaneous coronary interventions in relation to chronic kidney disease:
importance of periprocedural hemodynamic variables. Am J Cardiol 2004.
In press.
6. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to
prevent angiography-related renal tissue injury (the APART trial).
Am J Cardiol 2002;89:356–8.
7. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D,
Zidek W. Prevention of radiographic-contrast-agent-induced reduc-
tions in renal function by acetylcysteine. N Engl J Med 2000;343:
180–4.
8. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and
contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:
298–303.
9. McCullough PA, Sandberg KR. Epidemiology of contrast induced
nephropathy. Rev Cardiovasc Med 2003;4 Suppl 5:S3–9.
0. Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum
creatinine trajectory in acute contrast nephropathy. J Interv Cardiol
2002;15:349–54.
